ID   LGUL_HUMAN              Reviewed;         184 AA.
AC   Q04760; B2R6P7; B4DDV0; P78375; Q59EL0; Q5TZW3; Q96FC0; Q96J41;
DT   01-OCT-1993, integrated into UniProtKB/Swiss-Prot.
DT   06-MAR-2007, sequence version 4.
DT   07-APR-2021, entry version 211.
DE   RecName: Full=Lactoylglutathione lyase;
DE            EC=4.4.1.5;
DE   AltName: Full=Aldoketomutase;
DE   AltName: Full=Glyoxalase I;
DE            Short=Glx I;
DE   AltName: Full=Ketone-aldehyde mutase;
DE   AltName: Full=Methylglyoxalase;
DE   AltName: Full=S-D-lactoylglutathione methylglyoxal lyase;
GN   Name=GLO1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ALA-111.
RX   PubMed=7684374;
RA   Kim N.-S., Umezawa Y., Ohmura S., Kato S.;
RT   "Human glyoxalase I. cDNA cloning, expression, and sequence similarity to
RT   glyoxalase I from Pseudomonas putida.";
RL   J. Biol. Chem. 268:11217-11221(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ALA-111.
RC   TISSUE=Colon;
RX   PubMed=8449929;
RA   Ranganathan S., Walsh E.S., Godwin A.K., Tew K.D.;
RT   "Cloning and characterization of human colon glyoxalase-I.";
RL   J. Biol. Chem. 268:5661-5667(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=8670058; DOI=10.1042/bj3140463;
RA   Ridderstroem M., Mannervik B.;
RT   "Optimized heterologous expression of the human zinc enzyme glyoxalase I.";
RL   Biochem. J. 314:463-467(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ALA-111.
RX   PubMed=10564821; DOI=10.1016/s0378-1119(99)00420-5;
RA   Ranganathan S., Ciaccio P.J., Walsh E.S., Tew K.D.;
RT   "Genomic sequence of human glyoxalase-I: analysis of promoter activity and
RT   its regulation.";
RL   Gene 240:149-155(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANTS
RP   TYR-19 AND ALA-111.
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS TYR-19 AND
RP   ALA-111.
RC   TISSUE=Brain, Eye, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   PROTEIN SEQUENCE OF 13-18 AND 128-135, ACTIVITY REGULATION,
RP   BIOPHYSICOCHEMICAL PROPERTIES, MASS SPECTROMETRY, CLEAVAGE OF INITIATOR
RP   METHIONINE, ACETYLATION AT ALA-2, GLUTATHIONYLATION AT CYS-139, AND
RP   DISULFIDE BONDS.
RC   TISSUE=Erythrocyte;
RX   PubMed=20454679; DOI=10.1371/journal.pone.0010399;
RA   Birkenmeier G., Stegemann C., Hoffmann R., Gunther R., Huse K.,
RA   Birkemeyer C.;
RT   "Posttranslational modification of human glyoxalase 1 indicates redox-
RT   dependent regulation.";
RL   PLoS ONE 5:E10399-E10399(2010).
RN   [11]
RP   IDENTIFICATION OF NITRIC OXIDE-MODIFIED FORM, PHOSPHORYLATION, AND
RP   MUTAGENESIS OF CYS-19; CYS-20; CYS-61 AND CYS-139.
RX   PubMed=17576200; DOI=10.1042/bj20070379;
RA   de Hemptinne V., Rondas D., Vandekerckhove J., Vancompernolle K.;
RT   "Tumour necrosis factor induces phosphorylation primarily of the nitric-
RT   oxide-responsive form of glyoxalase I.";
RL   Biochem. J. 407:121-128(2007).
RN   [12]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [13]
RP   FUNCTION, PHOSPHORYLATION AT THR-107, AND MUTAGENESIS OF CYS-19; CYS-20;
RP   SER-45; SER-69; SER-94; THR-98; THR-102; THR-107 AND CYS-139.
RX   PubMed=19199007; DOI=10.1007/s11010-009-0031-7;
RA   de Hemptinne V., Rondas D., Toepoel M., Vancompernolle K.;
RT   "Phosphorylation on Thr-106 and NO-modification of glyoxalase I suppress
RT   the TNF-induced transcriptional activity of NF-kappaB.";
RL   Mol. Cell. Biochem. 325:169-178(2009).
RN   [14]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-148, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [17]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) IN COMPLEX WITH S-BENZYL-GLUTATHIONE
RP   AND ZINC.
RX   PubMed=9218781; DOI=10.1093/emboj/16.12.3386;
RA   Cameron A.D., Olin B., Ridderstroem M., Mannervik B., Jones T.A.;
RT   "Crystal structure of human glyoxalase I -- evidence for gene duplication
RT   and 3D domain swapping.";
RL   EMBO J. 16:3386-3395(1997).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) IN COMPLEX WITH ZINC AND
RP   S-HEXYLGLUTATHIONE, CATALYTIC ACTIVITY, FUNCTION, COFACTOR, ACTIVE SITE,
RP   SUBUNIT, AND MUTAGENESIS OF GLN-34; GLU-100 AND GLU-173.
RX   PubMed=9705294; DOI=10.1074/jbc.273.34.21623;
RA   Ridderstroem M., Cameron A.D., Jones T.A., Mannervik B.;
RT   "Involvement of an active-site Zn2+ ligand in the catalytic mechanism of
RT   human glyoxalase I.";
RL   J. Biol. Chem. 273:21623-21628(1998).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (1.72 ANGSTROMS) IN COMPLEXES WITH
RP   S-(N-HYDROXY-N-IODOPHENYLCARBAMOYL)GLUTATHIONE;
RP   S-P-NITROBENZYLOXYCARBONYLGLUTATHIONE AND ZINC, AND ACTIVE SITE.
RX   PubMed=10521255; DOI=10.1021/bi990696c;
RA   Cameron A.D., Ridderstroem M., Olin B., Kavarana M.J., Creighton D.J.,
RA   Mannervik B.;
RT   "Reaction mechanism of glyoxalase I explored by an X-ray crystallographic
RT   analysis of the human enzyme in complex with a transition state analogue.";
RL   Biochemistry 38:13480-13490(1999).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (1.47 ANGSTROMS) IN COMPLEX WITH SYNTHETIC INHIBITOR
RP   AND ZINC, FUNCTION, CATALYTIC ACTIVITY, SUBUNIT, AND COFACTOR.
RX   PubMed=23122816; DOI=10.1016/j.bmcl.2012.10.045;
RA   Chiba T., Ohwada J., Sakamoto H., Kobayashi T., Fukami T.A., Irie M.,
RA   Miura T., Ohara K., Koyano H.;
RT   "Design and evaluation of azaindole-substituted N-hydroxypyridones as
RT   glyoxalase I inhibitors.";
RL   Bioorg. Med. Chem. Lett. 22:7486-7489(2012).
CC   -!- FUNCTION: Catalyzes the conversion of hemimercaptal, formed from
CC       methylglyoxal and glutathione, to S-lactoylglutathione. Involved in the
CC       regulation of TNF-induced transcriptional activity of NF-kappa-B.
CC       Required for normal osteoclastogenesis. {ECO:0000269|PubMed:19199007,
CC       ECO:0000269|PubMed:23122816, ECO:0000269|PubMed:9705294}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(R)-S-lactoylglutathione = glutathione + methylglyoxal;
CC         Xref=Rhea:RHEA:19069, ChEBI:CHEBI:17158, ChEBI:CHEBI:57474,
CC         ChEBI:CHEBI:57925; EC=4.4.1.5; Evidence={ECO:0000269|PubMed:23122816,
CC         ECO:0000269|PubMed:9705294};
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000269|PubMed:23122816, ECO:0000269|PubMed:9705294};
CC       Note=Binds 1 zinc ion per subunit. In the homodimer, two zinc ions are
CC       bound between subunits. {ECO:0000269|PubMed:23122816,
CC       ECO:0000269|PubMed:9705294};
CC   -!- ACTIVITY REGULATION: Regulated by oxidation of Cys-139 in response to
CC       the redox state of the cell. Results in the alternative formation of
CC       cystine or glutathione-bound cysteine, the latter modification leading
CC       to reduced enzyme activity. {ECO:0000269|PubMed:20454679}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=1.3 mM for methylglyoxal/glutathione (native form)
CC         {ECO:0000269|PubMed:20454679};
CC         KM=0.7 mM for methylglyoxal/glutathione (reduced form)
CC         {ECO:0000269|PubMed:20454679};
CC         Vmax=0.335 umol/min/mg enzyme with methylglyoxal/glutathione as
CC         substrate (native form) {ECO:0000269|PubMed:20454679};
CC         Vmax=0.7 umol/min/mg enzyme with methylglyoxal/glutathione as
CC         substrate (reduced form) {ECO:0000269|PubMed:20454679};
CC         Note=Reduction of GLO1 was carried out by incubation with 20 mM
CC         betamercaptoethanol prior to kinetic analysis.;
CC   -!- PATHWAY: Secondary metabolite metabolism; methylglyoxal degradation;
CC       (R)-lactate from methylglyoxal: step 1/2.
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:23122816,
CC       ECO:0000269|PubMed:9218781, ECO:0000269|PubMed:9705294}.
CC   -!- INTERACTION:
CC       Q04760; Q3MIT2: PUS10; NbExp=3; IntAct=EBI-1055525, EBI-11983583;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q04760-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q04760-2; Sequence=VSP_041632;
CC   -!- PTM: Glutathionylation at Cys-139 inhibits enzyme activity.
CC       {ECO:0000269|PubMed:20454679}.
CC   -!- PTM: Phosphorylated at Thr-107 in the presence of CaMK2. However, this
CC       is a consensus site for phosphorylation by CK2 so phosphorylation may
CC       be mediated by CK2 rather than CaMK2. Phosphorylation is induced by TNF
CC       and suppresses the TNF-induced transcriptional activity of NF-kappa-B.
CC       {ECO:0000269|PubMed:17576200, ECO:0000269|PubMed:19199007}.
CC   -!- PTM: Exists in a nitric oxide (NO)-modified form. The exact nature of
CC       the modification is unknown, but it suppresses the TNF-induced
CC       transcriptional activity of NF-kappa-B.
CC   -!- MASS SPECTROMETRY: [Isoform 1]: Mass=20687.4; Method=Electrospray;
CC       Note=Variant Glu-111. The measured range is 2-184.;
CC       Evidence={ECO:0000269|PubMed:20454679};
CC   -!- MASS SPECTROMETRY: [Isoform 1]: Mass=20629.7; Method=Electrospray;
CC       Note=Variant Ala-111. The measured range is 2-184.;
CC       Evidence={ECO:0000269|PubMed:20454679};
CC   -!- POLYMORPHISM: Exists in three separable isoforms which originate from
CC       two alleles in the genome. These correspond to two homodimers and one
CC       heterodimer composed of two subunits showing different electrophoretic
CC       properties.
CC   -!- SIMILARITY: Belongs to the glyoxalase I family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD93038.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D13315; BAA02572.1; -; mRNA.
DR   EMBL; L07837; AAA52565.1; -; mRNA.
DR   EMBL; S83285; AAB49495.1; -; mRNA.
DR   EMBL; AF146651; AAD38008.1; -; Genomic_DNA.
DR   EMBL; AB209801; BAD93038.1; ALT_INIT; mRNA.
DR   EMBL; AK293345; BAG56861.1; -; mRNA.
DR   EMBL; AK312662; BAG35544.1; -; mRNA.
DR   EMBL; BT019987; AAV38790.1; -; mRNA.
DR   EMBL; BT019988; AAV38791.1; -; mRNA.
DR   EMBL; AL391415; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC001741; AAH01741.1; -; mRNA.
DR   EMBL; BC011365; AAH11365.1; -; mRNA.
DR   EMBL; BC015934; AAH15934.1; -; mRNA.
DR   CCDS; CCDS4837.1; -. [Q04760-1]
DR   PIR; A46714; A46714.
DR   PIR; S63603; S63603.
DR   RefSeq; NP_006699.2; NM_006708.2. [Q04760-1]
DR   PDB; 1BH5; X-ray; 2.20 A; A/B/C/D=2-184.
DR   PDB; 1FRO; X-ray; 2.20 A; A/B/C/D=2-184.
DR   PDB; 1QIN; X-ray; 2.00 A; A/B=2-184.
DR   PDB; 1QIP; X-ray; 1.72 A; A/B/C/D=2-184.
DR   PDB; 3VW9; X-ray; 1.47 A; A/B=1-184.
DR   PDB; 3W0T; X-ray; 1.35 A; A/B/C/D=1-184.
DR   PDB; 3W0U; X-ray; 1.70 A; A/B=1-184.
DR   PDBsum; 1BH5; -.
DR   PDBsum; 1FRO; -.
DR   PDBsum; 1QIN; -.
DR   PDBsum; 1QIP; -.
DR   PDBsum; 3VW9; -.
DR   PDBsum; 3W0T; -.
DR   PDBsum; 3W0U; -.
DR   SMR; Q04760; -.
DR   BioGRID; 109001; 60.
DR   IntAct; Q04760; 15.
DR   MINT; Q04760; -.
DR   STRING; 9606.ENSP00000362463; -.
DR   BindingDB; Q04760; -.
DR   ChEMBL; CHEMBL2424; -.
DR   DrugBank; DB00143; Glutathione.
DR   DrugBank; DB00328; Indomethacin.
DR   DrugBank; DB03345; Mercaptoethanol.
DR   DrugBank; DB08179; methyl 4-(2,3-dihydroxy-5-methylphenoxy)-2-hydroxy-6-methylbenzoate.
DR   DrugBank; DB03330; S-(N-hydroxy-N-iodophenylcarbamoyl)glutathione.
DR   DrugBank; DB03602; S-benzylglutathione.
DR   DrugBank; DB04132; S-Hexylglutathione.
DR   DrugBank; DB03130; S-P-Nitrobenzyloxycarbonylglutathione.
DR   DrugCentral; Q04760; -.
DR   iPTMnet; Q04760; -.
DR   MetOSite; Q04760; -.
DR   PhosphoSitePlus; Q04760; -.
DR   SwissPalm; Q04760; -.
DR   BioMuta; GLO1; -.
DR   DMDM; 134039205; -.
DR   OGP; Q04760; -.
DR   REPRODUCTION-2DPAGE; IPI00220766; -.
DR   REPRODUCTION-2DPAGE; Q04760; -.
DR   CPTAC; CPTAC-1416; -.
DR   CPTAC; CPTAC-1417; -.
DR   CPTAC; CPTAC-1418; -.
DR   CPTAC; CPTAC-1419; -.
DR   CPTAC; CPTAC-1420; -.
DR   EPD; Q04760; -.
DR   jPOST; Q04760; -.
DR   MassIVE; Q04760; -.
DR   PaxDb; Q04760; -.
DR   PeptideAtlas; Q04760; -.
DR   PRIDE; Q04760; -.
DR   ProteomicsDB; 58281; -. [Q04760-1]
DR   ProteomicsDB; 58282; -. [Q04760-2]
DR   Antibodypedia; 29872; 487 antibodies.
DR   CPTC; Q04760; 3 antibodies.
DR   DNASU; 2739; -.
DR   Ensembl; ENST00000373365; ENSP00000362463; ENSG00000124767. [Q04760-1]
DR   GeneID; 2739; -.
DR   KEGG; hsa:2739; -.
DR   CTD; 2739; -.
DR   DisGeNET; 2739; -.
DR   GeneCards; GLO1; -.
DR   HGNC; HGNC:4323; GLO1.
DR   HPA; ENSG00000124767; Low tissue specificity.
DR   MIM; 138750; gene.
DR   neXtProt; NX_Q04760; -.
DR   OpenTargets; ENSG00000124767; -.
DR   PharmGKB; PA28724; -.
DR   VEuPathDB; HostDB:ENSG00000124767.6; -.
DR   eggNOG; KOG2944; Eukaryota.
DR   GeneTree; ENSGT00390000009312; -.
DR   HOGENOM; CLU_046006_1_1_1; -.
DR   InParanoid; Q04760; -.
DR   OMA; NWGTESY; -.
DR   PhylomeDB; Q04760; -.
DR   TreeFam; TF105011; -.
DR   BRENDA; 4.4.1.5; 2681.
DR   PathwayCommons; Q04760; -.
DR   Reactome; R-HSA-70268; Pyruvate metabolism.
DR   SABIO-RK; Q04760; -.
DR   UniPathway; UPA00619; UER00675.
DR   BioGRID-ORCS; 2739; 5 hits in 988 CRISPR screens.
DR   ChiTaRS; GLO1; human.
DR   EvolutionaryTrace; Q04760; -.
DR   GeneWiki; GLO1; -.
DR   GeneWiki; Lactoylglutathione_lyase; -.
DR   GenomeRNAi; 2739; -.
DR   Pharos; Q04760; Tchem.
DR   PRO; PR:Q04760; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; Q04760; protein.
DR   Bgee; ENSG00000124767; Expressed in prostate gland and 248 other tissues.
DR   ExpressionAtlas; Q04760; baseline and differential.
DR   Genevisible; Q04760; HS.
DR   GO; GO:0005737; C:cytoplasm; TAS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0004462; F:lactoylglutathione lyase activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0005975; P:carbohydrate metabolic process; NAS:ProtInc.
DR   GO; GO:0006749; P:glutathione metabolic process; IEA:Ensembl.
DR   GO; GO:0009438; P:methylglyoxal metabolic process; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0030316; P:osteoclast differentiation; ISS:UniProtKB.
DR   GO; GO:0006090; P:pyruvate metabolic process; TAS:Reactome.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   Gene3D; 3.10.180.10; -; 1.
DR   InterPro; IPR029068; Glyas_Bleomycin-R_OHBP_Dase.
DR   InterPro; IPR004360; Glyas_Fos-R_dOase_dom.
DR   InterPro; IPR004361; Glyoxalase_1.
DR   InterPro; IPR018146; Glyoxalase_1_CS.
DR   InterPro; IPR037523; VOC.
DR   Pfam; PF00903; Glyoxalase; 1.
DR   SUPFAM; SSF54593; SSF54593; 1.
DR   TIGRFAMs; TIGR00068; glyox_I; 1.
DR   PROSITE; PS00934; GLYOXALASE_I_1; 1.
DR   PROSITE; PS00935; GLYOXALASE_I_2; 1.
DR   PROSITE; PS51819; VOC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Direct protein sequencing;
KW   Disulfide bond; Glutathionylation; Lyase; Metal-binding; Phosphoprotein;
KW   Reference proteome; Zinc.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|PubMed:20454679,
FT                   ECO:0007744|PubMed:19413330, ECO:0007744|PubMed:25944712"
FT   CHAIN           2..184
FT                   /note="Lactoylglutathione lyase"
FT                   /id="PRO_0000168076"
FT   DOMAIN          31..177
FT                   /note="VOC"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01163"
FT   REGION          157..158
FT                   /note="Substrate binding"
FT   ACT_SITE        173
FT                   /note="Proton donor/acceptor"
FT                   /evidence="ECO:0000269|PubMed:10521255,
FT                   ECO:0000269|PubMed:9705294"
FT   METAL           34
FT                   /note="Zinc; shared with dimeric partner"
FT                   /evidence="ECO:0000269|PubMed:23122816,
FT                   ECO:0000269|PubMed:9218781, ECO:0000269|PubMed:9705294"
FT   METAL           100
FT                   /note="Zinc; shared with dimeric partner"
FT                   /evidence="ECO:0000269|PubMed:23122816,
FT                   ECO:0000269|PubMed:9218781, ECO:0000269|PubMed:9705294"
FT   METAL           127
FT                   /note="Zinc; via tele nitrogen"
FT                   /evidence="ECO:0000269|PubMed:23122816,
FT                   ECO:0000269|PubMed:9218781, ECO:0000269|PubMed:9705294"
FT   METAL           173
FT                   /note="Zinc"
FT                   /evidence="ECO:0000269|PubMed:23122816,
FT                   ECO:0000269|PubMed:9218781, ECO:0000269|PubMed:9705294"
FT   BINDING         34
FT                   /note="Substrate; shared with dimeric partner"
FT   BINDING         38
FT                   /note="Substrate; shared with dimeric partner"
FT   BINDING         104
FT                   /note="Substrate; shared with dimeric partner"
FT   BINDING         123
FT                   /note="Substrate"
FT   BINDING         127
FT                   /note="Substrate"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000269|PubMed:20454679,
FT                   ECO:0007744|PubMed:19413330, ECO:0007744|PubMed:25944712"
FT   MOD_RES         88
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9CPU0"
FT   MOD_RES         107
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:19199007"
FT   MOD_RES         139
FT                   /note="S-glutathionyl cysteine; alternate"
FT                   /evidence="ECO:0000269|PubMed:20454679"
FT   MOD_RES         148
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         148
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q9CPU0"
FT   DISULFID        19..20
FT                   /evidence="ECO:0000269|PubMed:20454679"
FT   DISULFID        61..139
FT                   /note="Alternate"
FT                   /evidence="ECO:0000269|PubMed:20454679"
FT   VAR_SEQ         105..119
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_041632"
FT   VARIANT         19
FT                   /note="C -> Y (in dbSNP:rs17855424)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:15489334"
FT                   /id="VAR_031078"
FT   VARIANT         111
FT                   /note="E -> A (in dbSNP:rs4746)"
FT                   /evidence="ECO:0000269|PubMed:10564821,
FT                   ECO:0000269|PubMed:14702039, ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:7684374, ECO:0000269|PubMed:8449929"
FT                   /id="VAR_013481"
FT   MUTAGEN         19
FT                   /note="C->A: No effect on NO-mediated modification.
FT                   Impaired NO-mediated modification; when associated with A-
FT                   20. Loss of NO-mediated modification; when associated with
FT                   A-139."
FT                   /evidence="ECO:0000269|PubMed:17576200,
FT                   ECO:0000269|PubMed:19199007"
FT   MUTAGEN         20
FT                   /note="C->A: No effect on NO-mediated modification.
FT                   Impaired NO-mediated modification; when associated with A-
FT                   19. Loss of NO-mediated modification; when associated with
FT                   A-139."
FT                   /evidence="ECO:0000269|PubMed:17576200,
FT                   ECO:0000269|PubMed:19199007"
FT   MUTAGEN         34
FT                   /note="Q->E: Reduces enzyme activity by 99%."
FT                   /evidence="ECO:0000269|PubMed:9705294"
FT   MUTAGEN         45
FT                   /note="S->A: No effect on phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:19199007"
FT   MUTAGEN         61
FT                   /note="C->A: No effect on NO-mediated modification."
FT                   /evidence="ECO:0000269|PubMed:17576200"
FT   MUTAGEN         69
FT                   /note="S->A: No effect on phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:19199007"
FT   MUTAGEN         94
FT                   /note="S->A: No effect on phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:19199007"
FT   MUTAGEN         98
FT                   /note="T->A: No effect on phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:19199007"
FT   MUTAGEN         100
FT                   /note="E->Q: Reduces enzyme activity by over 99%."
FT                   /evidence="ECO:0000269|PubMed:9705294"
FT   MUTAGEN         102
FT                   /note="T->A: No effect on phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:19199007"
FT   MUTAGEN         107
FT                   /note="T->A: Loss of phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:19199007"
FT   MUTAGEN         139
FT                   /note="C->A: Impaired NO-mediated modification. Loss of NO-
FT                   mediated modification; when associated with A-19 or A-20."
FT                   /evidence="ECO:0000269|PubMed:17576200,
FT                   ECO:0000269|PubMed:19199007"
FT   MUTAGEN         173
FT                   /note="E->Q: Abolishes enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:9705294"
FT   HELIX           13..18
FT                   /evidence="ECO:0007744|PDB:3W0T"
FT   HELIX           25..27
FT                   /evidence="ECO:0007744|PDB:3W0T"
FT   STRAND          31..38
FT                   /evidence="ECO:0007744|PDB:3W0T"
FT   HELIX           42..51
FT                   /evidence="ECO:0007744|PDB:3W0T"
FT   STRAND          56..63
FT                   /evidence="ECO:0007744|PDB:3W0T"
FT   TURN            64..67
FT                   /evidence="ECO:0007744|PDB:3W0T"
FT   STRAND          68..75
FT                   /evidence="ECO:0007744|PDB:3W0T"
FT   HELIX           78..80
FT                   /evidence="ECO:0007744|PDB:3W0T"
FT   HELIX           85..92
FT                   /evidence="ECO:0007744|PDB:3W0T"
FT   STRAND          95..104
FT                   /evidence="ECO:0007744|PDB:3W0T"
FT   HELIX           107..109
FT                   /evidence="ECO:0007744|PDB:3W0T"
FT   STRAND          118..122
FT                   /evidence="ECO:0007744|PDB:3W0T"
FT   STRAND          124..131
FT                   /evidence="ECO:0007744|PDB:3W0T"
FT   HELIX           135..144
FT                   /evidence="ECO:0007744|PDB:3W0T"
FT   STRAND          149..151
FT                   /evidence="ECO:0007744|PDB:3W0T"
FT   STRAND          155..158
FT                   /evidence="ECO:0007744|PDB:3W0T"
FT   STRAND          162..165
FT                   /evidence="ECO:0007744|PDB:3W0T"
FT   STRAND          171..175
FT                   /evidence="ECO:0007744|PDB:3W0T"
FT   HELIX           177..179
FT                   /evidence="ECO:0007744|PDB:3W0T"
FT   HELIX           181..183
FT                   /evidence="ECO:0007744|PDB:3W0T"
SQ   SEQUENCE   184 AA;  20778 MW;  46291B7878070028 CRC64;
     MAEPQPPSGG LTDEAALSCC SDADPSTKDF LLQQTMLRVK DPKKSLDFYT RVLGMTLIQK
     CDFPIMKFSL YFLAYEDKND IPKEKDEKIA WALSRKATLE LTHNWGTEDD ETQSYHNGNS
     DPRGFGHIGI AVPDVYSACK RFEELGVKFV KKPDDGKMKG LAFIQDPDGY WIEILNPNKM
     ATLM
//
